CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 557 enrolled
Drug / intervention
Apixabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01884337
NCT01884337Phase 4Completed
CompareCT.gov

A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Bristol-Myers Squibb·interventional·Posted Jun 24, 2013·Updated Nov 29, 2019

In Brief

A Phase 4 clinical trial evaluating Apixaban for Anticoagulation. Completed, enrolled 557 participants across 20 sites.

Detailed Summary

The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnticoagulation
CountriesIndia
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 24, 2013
Enrollment StartMar 24, 2015
Primary CompletionJun 4, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.0 years ago

Interventions

Apixabandrug